Edition:
India

Trovagene Inc (TROV.OQ)

TROV.OQ on NASDAQ Stock Exchange Capital Market

0.32USD
1:30am IST
Change (% chg)

$-0.01 (-1.74%)
Prev Close
$0.33
Open
$0.32
Day's High
$0.33
Day's Low
$0.32
Volume
70,693
Avg. Vol
384,835
52-wk High
$1.63
52-wk Low
$0.24

Chart for

About

Trovagene, Inc. is a clinical-stage, precision medicine oncology therapeutics company. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and in synergy combinations with more... (more)

Overall

Beta: 0.37
Market Cap(Mil.): $31.68
Shares Outstanding(Mil.): 37.27
Dividend: --
Yield (%): --

Financials

BRIEF-Trovagene Reports Q4 Loss Per Share $0.06

* TROVAGENE ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2017 RESULTS

27 Feb 2018

BRIEF-Trovagene Completes Cycle-One Dosing In First Patient Enrolled In Phase 1B/2 Clinical Trial Of PCM-075

* TROVAGENE ANNOUNCES COMPLETION OF CYCLE-ONE DOSING IN FIRST PATIENT ENROLLED IN ITS PHASE 1B/2 CLINICAL TRIAL OF PCM-075 IN ACUTE MYELOID LEUKEMIA (AML) Source text for Eikon: Further company coverage:

06 Feb 2018

BRIEF-Trovagene Initiates Unite Phase 2 Clinical Trial Of PCM-075 In Patients With Metastatic Castration-Resistant Prostate Cancer

* TROVAGENE ANNOUNCES INITIATION OF UNITE PHASE 2 CLINICAL TRIAL OF PCM-075 IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) Source text for Eikon: Further company coverage:

24 Jan 2018

BRIEF-Trovagene Prices $4.5 Million Public Offering

* PRICING OF PUBLIC OFFERING OF 15 MILLION SHARES OF ITS COMMON STOCK, COMMON WARRANTS TO PURCHASE UP TO 15 MILLION SHARES OF COMMON STOCK

15 Dec 2017

BRIEF-Trovagene Submits Protocol To FDA For Phase 2 Clinical Trial Of Pcm-075 In Combination With Zytiga®

* TROVAGENE SUBMITS PROTOCOL TO FDA FOR PHASE 2 CLINICAL TRIAL OF PCM-075 IN COMBINATION WITH ZYTIGA® FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

14 Dec 2017

BRIEF-Trovagene's preclinical data to be featured at San Antonio Breast Cancer Symposium

* TROVAGENE PRESENTS DATA SHOWING SENSITIVITY OF TRIPLE NEGATIVE BREAST CANCER (TNBC) CELL LINES TO PCM-075 AND SYNERGY WITH ZYTIGA® AT SAN ANTONIO BREAST CANCER SYMPOSIUM (SABCS) Source text for Eikon: Further company coverage:

08 Dec 2017

BRIEF-Trovagene Inc updates on clinical trial for PCM-075

* Trovagene announces activation of first clinical trial site in phase 1B/2 acute myeloid leukemia (AML) trial for PCM-075

13 Nov 2017

BRIEF-TROVAGENE REPORTS Q3 LOSS PER SHARE $0.12

* ‍AS OF SEPTEMBER 30, 2017, TROVAGENE HAD APPROXIMATELY $7.4 MILLION OF CASH AND CASH EQUIVALENTS​ Source text: (http://bit.ly/2hgteK4) Further company coverage:

09 Nov 2017

BRIEF-Trovagene files for offering of up to $17.5 mln- SEC filing

* Trovagene Inc files for offering of up to $17.5 million - SEC filing Source text: (http://bit.ly/2zOQs1P) Further company coverage:

26 Oct 2017

Earnings vs. Estimates